A Phase 3 interventional study of Corifollitropin alfa and hCG in Hypogonadotropic Hypogonadism, sponsored by Organon and Co. Completed at 15 sites in 6 countries. Open to male participants aged 14 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-23.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to investigate whether corifollitropin alfa (MK-8962), administered alone for 12 weeks and then in combination with human chorionic gonadotropin (hCG) for 52 weeks, increases the testicular volume in adolescent males aged 14 to \<18. In addition, the study will evaluate participants for safety, tolerability and for the development of corifollitropin alfa antibodies. No formal hypothesis will be tested for this estimation study
320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.
This study's enrollment of 17 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.
Browse Hypogonadism studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was \>60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.
Drug: Corifollitropin alfa · Drug: hCG
CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
Also known as: MK-8962, Elonva
hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
Change From Baseline in Log-Transformed Testicular Volume (TV) to Week 64
Participants underwent testicular ultrasound of left and right testes at pre-specified time points to measure TV. TV was measured as the sum of volumes of left and right testes. The linear mixed model with a fixed effect for baseline and Week 64 and a random effect for participant was used to calculate the mean change in log-transformed TV and associated 95% confidence intervals (CIs) from baseline to Week 64. The geometric mean ratio and its 95% CIs for TV were obtained by exponentiation. The ratio \> 1 indicated an increase in TV from baseline.
Time frame: Baseline and Week 64
Number of Participants Who Experienced an Adverse Event (AE)
An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was reported.
Time frame: Up to approximately 71 Weeks
Number of Participants Who Discontinued Study Treatment Due to an AE
An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE was reported.
Time frame: Up to approximately 64 Weeks
Percentage of Participants With Anti-Corifollitropin Alfa (CFA) Antibodies
Blood samples were collected at pre-specified time points to assess anti-CFA antibodies. The percentage of participants with anti-CFA antibodies after administration of CFA were reported.
Time frame: Up to approximately 71 Weeks
Change From Baseline in Serum Inhibin B Concentration to Week 64
Serum Inhibin B concentration is a surrogate marker for spermatogenesis in males. Blood samples were collected at baseline and Week 64 post dose to report the mean change from baseline in serum inhibin concentration to Week 64. A mean change from baseline in serum inhibin B concentration to Week 64 was reported. A positive value indicated a higher serum inhibin concentration level.
Time frame: Baseline and Week 64
Growth Velocity at Week 36
Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 36-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (yr) and age as covariates.
Time frame: Week 36
Growth Velocity at Week 64
Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 64-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (year) and age as covariates.
Time frame: Week 64
Change From Baseline in Tanner Stage (TS) of Pubertal Development for Pubic Hair to Week 12, Week 36, and Week 64
Male participants were assessed clinically for pubertal development using the TS for pubic hair (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal state, Tanner II: small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum, Tanner III: hair becomes more coarse and curly, and begins to extend laterally, Tanner IV: adult-like hair quality, extending across pubis but sparing medial thighs and Tanner V: hair extends to medial surface of the thigh. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.
Time frame: Baseline, Week 12, Week 36, and Week 64
Change From Baseline in TS of Pubertal Development for Genital Growth to Week 12, Week 36, and Week 64
Male participants were assessed clinically for pubertal development using TS for genital growth (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal (TV \<1.5 ml; small penis), Tanner II: TV 1.6-6ml; skin on scrotum thins, reddens and enlarges; penis length unchanged, Tanner III: TV 6-12ml; scrotum enlarges further; penis begins to lengthen Tanner IV: TV 12-20ml; scrotum enlarges further and darkens; penis increases in length and circumference, and Tanner V: TV \>20ml; adult scrotum and penis. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.
Time frame: Baseline, Week 12, Week 36, and Week 64
Mean Serum Concentration of CFA
Blood samples were collected at pre-specified time points (Day 1 (predose, 6-24 hours postdose after 1st dose), Day 3 (32-52 hours postdose after 1st dose), Day 5 (72-120 hours postdose after 1st dose), Day 8 (144-192 hours postdose after 1st dose), Day 11 (216-244 hours postdose after 1st dose), Day 29 (predose prior to 2nd dose; no hCG), Day 85 (predose, prior to 4th dose; no hCG), Day 169 (predose prior to 7th dose; with hCG co-administration), Day 253 (predose prior to 10th dose with hCG co-administration), Day 337 (predose prior to 13th dose; with hCG co-administration), Days 449 and 456 (postdose)) to report the mean serum concentration of CFA.
Time frame: Day 1: predose, 6-24 hours postdose; Day 3: 32-52 hours postdose; Day 5: 72-120 hours postdose; Day 8: 144-192 hours postdose; Day 11: 216-244 hours postdose; Days 29, 85, 169, 253, 337: predose; Days 449, 456: postdose
Change From Baseline in Testicular Echogenicity to Week 12, Week 36, and Week 64
Testicular Echogenicity was determined by evaluating the sonographic patterns obtained on testicular ultrasound of right and left testes at baseline, Week 12, Week 36 and 64. The sonographic patterns were assessed by central imaging unit by an independent radiologist and categorized as Hypoechoic (decreased echogenicity as compared to echogenicity at baseline), Isoechoic (same echogenicity as compared to echogenicity at baseline) and Hyperechoic (increased echogenicity as compared to echogenicity at baseline). The number of participants with a sonographic pattern at Weeks 12, 36 and 64 were reported.
Time frame: Baseline, Week 12, Week 36, and Week 64
Change From Baseline in Luteinizing Hormone (LH) to Week 12, Week 36, and Week 64
LH is a gonadotropin secreted from the anterior pituitary and is a marker for spontaneous puberty. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in LH level to Weeks 12, 36 and 64.
Time frame: Baseline, Week 12, Week 36, and Week 64
Change From Baseline in Calculated Free Testosterone (T) to Week 12, Week 36, and Week 64
Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in T level to Weeks 12, 36 and 64. The change from baseline in T level to Week 12, 36, and 64 could not be calculated as planned because only 2 participants had baseline T level values which were insufficient to provide the trend change from baseline in T level to Week 12, 36, and 64.
Time frame: Baseline, Week 12, Week 36, and Week 64
Change From Baseline in Total Testosterone (Total T) to Week 12, Week 36, and Week 64
Total T is a marker for progress of puberty in males. Total T levels increase during puberty as the testes respond to the gonadotropins. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 post dose to report the mean change from baseline in Total T level to Weeks 12, 36 and 64. A negative value indicated a lower Total T level.
Time frame: Baseline, Week 12, Week 36, and Week 64
Change From Baseline in Estradiol (E2) to Week 12, Week 36, and Week 64
E2 levels rise during puberty in males when some of the T secreted is aromatized. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in E2 level to Weeks 12, 36 and 64. A positive value indicated a higher E2 level.
Time frame: Baseline, Week 12, Week 36, and Week 64
Change From Baseline in Sex Hormone-Binding Globulin (SHBG) to Week 12, Week 36, and Week 64
SHBG is a blood protein that controls the amount of T body tissues in males. SHBG is regulated by the ratio of T and E2 levels in addition to other factors (thyroid hormone status, dietary factors, certain diseases and medications). Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in SHBG level to Weeks 12, 36 and 64. A negative value indicated a lower SHBG level.
Time frame: Baseline, Week 12, Week 36, and Week 64
Change From Baseline in Anti-Müllerian Hormone (AMH) to Week 12, Week 36, and Week 64
AMH is a marker for progress of puberty in males. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in AMH level to Weeks 12, 36 and 64. A negative value indicated a lower AMH level.
Time frame: Baseline, Week 12, Week 36, and Week 64
| Milestone | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Started | 17 |
| Completed | 17 |
| Not completed | 0 |
Participants underwent testicular ultrasound of left and right testes at pre-specified time points to measure TV. TV was measured as the sum of volumes of left and right testes. The linear mixed model with a fixed effect for baseline and Week 64 and a random effect for participant was used to calculate the mean change in log-transformed TV and associated 95% confidence intervals (CIs) from baseline to Week 64. The geometric mean ratio and its 95% CIs for TV were obtained by exponentiation. The ratio \> 1 indicated an increase in TV from baseline.
| mL | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline | 1.5 ± 0.7 |
| Week 64 | 14.5 ± 6.8 |
An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was reported.
| Participants | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 16 |
An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE was reported.
| Participants | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 1 |
Blood samples were collected at pre-specified time points to assess anti-CFA antibodies. The percentage of participants with anti-CFA antibodies after administration of CFA were reported.
| Percentage of Participants | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Percentage of Participants With Anti-Corifollitropin Alfa (CFA) Antibodies | 0 |
Serum Inhibin B concentration is a surrogate marker for spermatogenesis in males. Blood samples were collected at baseline and Week 64 post dose to report the mean change from baseline in serum inhibin concentration to Week 64. A mean change from baseline in serum inhibin B concentration to Week 64 was reported. A positive value indicated a higher serum inhibin concentration level.
| ng/L | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline | 31.92 ± 35.30 |
| Baseline to Week 64 | 91.46 ± 59.25 |
Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 36-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (yr) and age as covariates.
| cm/year | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Growth Velocity at Week 36 | 8.3 ± 1.1 |
Growth velocity is the rate of change in height measurement and is a marker for pubertal progress. Height was measured using a wall-mounted calibrated stadiometer. A mixed model was used to assess the overall growth velocity slope over the 64-week treatment period using the slopes estimated from an overall mixed random intercept and random slope model of height (cm) and time (year) and age as covariates.
| cm/year | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Growth Velocity at Week 64 | 7.6 ± 1.0 |
Male participants were assessed clinically for pubertal development using the TS for pubic hair (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal state, Tanner II: small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum, Tanner III: hair becomes more coarse and curly, and begins to extend laterally, Tanner IV: adult-like hair quality, extending across pubis but sparing medial thighs and Tanner V: hair extends to medial surface of the thigh. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.
| Participants | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline (BL) Tanner I | 6 |
| BL Tanner II | 6 |
| BL Tanner III | 1 |
| BL Tanner IV | 0 |
| BL Tanner V | 0 |
| BL Tanner I to Week 12 Tanner I | 5 |
| BL Tanner I to Week 12 Tanner II | 1 |
| BL Tanner II to Week 12 Tanner II | 5 |
| BL Tanner II to Week 12 Tanner III | 1 |
| BL Tanner III to Week 12 Tanner III | 1 |
| BL Tanner I to Week 36 Tanner II | 2 |
| BL Tanner I to Week 36 Tanner III | 4 |
| BL Tanner II to Week 36 Tanner II | 2 |
| BL Tanner II to Week 36 Tanner III | 4 |
| BL Tanner III to Week 36 Tanner IV | 1 |
| BL Tanner I to Week 64 Tanner III | 3 |
| BL Tanner I to Week 64 Tanner IV | 1 |
| BL Tanner I to Week 64 Tanner V | 2 |
| BL Tanner II to Week 64 Tanner III | 1 |
| BL Tanner II to Week 64 Tanner IV | 3 |
| BL Tanner II to Week 64 Tanner V | 1 |
| BL Tanner II to Week 64 Unknown | 1 |
| BL Tanner III to Week 64 Tanner IV | 1 |
Male participants were assessed clinically for pubertal development using TS for genital growth (range: Tanner I-V). TS describes sexual maturity stages (no better or worse outcome) as: Tanner I: prepubertal (TV \<1.5 ml; small penis), Tanner II: TV 1.6-6ml; skin on scrotum thins, reddens and enlarges; penis length unchanged, Tanner III: TV 6-12ml; scrotum enlarges further; penis begins to lengthen Tanner IV: TV 12-20ml; scrotum enlarges further and darkens; penis increases in length and circumference, and Tanner V: TV \>20ml; adult scrotum and penis. The number of participants in each Tanner stage at baseline and categorical change from baseline in Tanner stages to Weeks 12, 36 and 64 were reported.
| Participants | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline (BL) Tanner I | 12 |
| BL Tanner II | 1 |
| BL Tanner III | 0 |
| BL Tanner IV | 0 |
| BL Tanner V | 0 |
| BL Tanner I to Week 12 Tanner I | 9 |
| BL Tanner I to Week 12 Tanner II | 3 |
| BL Tanner II to Week 12 Tanner II | 1 |
| BL Tanner I to Week 36 Tanner I | 2 |
| BL Tanner I to Week 36 Tanner II | 1 |
| BL Tanner I to Week 36 Tanner III | 8 |
| BL Tanner I to Week 36 Tanner IV | 1 |
| BL Tanner II to Week 36 Tanner II | 1 |
| BL Tanner I to Week 64 Tanner II | 1 |
| BL Tanner I to Week 64 Tanner III | 4 |
| BL Tanner I to Week 64 Tanner IV | 4 |
| BL Tanner I to Week 64 Tanner V | 2 |
| BL Tanner I to Week 64 Unknown | 1 |
| BL Tanner II to Week 64 Tanner III | 1 |
Blood samples were collected at pre-specified time points (Day 1 (predose, 6-24 hours postdose after 1st dose), Day 3 (32-52 hours postdose after 1st dose), Day 5 (72-120 hours postdose after 1st dose), Day 8 (144-192 hours postdose after 1st dose), Day 11 (216-244 hours postdose after 1st dose), Day 29 (predose prior to 2nd dose; no hCG), Day 85 (predose, prior to 4th dose; no hCG), Day 169 (predose prior to 7th dose; with hCG co-administration), Day 253 (predose prior to 10th dose with hCG co-administration), Day 337 (predose prior to 13th dose; with hCG co-administration), Days 449 and 456 (postdose)) to report the mean serum concentration of CFA.
| ng/L | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Predose Day 1 | 0.0 ± 0.0 |
| Postdose Day 1 (6-24 hours) | 4100 ± 2630 |
| Postdose Day 3 (32-52 hours) | 5880 ± 1640 |
| Postdose Day 5 (72-120 hours) | 4240 ± 1180 |
| Postdose Day 8 (144-192 hours) | 2110 ± 864 |
| Postdose Day 11 (216-264 hours) | 1150 ± 655 |
| Predose Day 29 | 480 ± 348 |
| Predose Day 85 | 695 ± 1310 |
| Predose Day 169 | 691 ± 1060 |
| Predose Day 253 | 301 ± 297 |
| Predose Day 337 | 556 ± 1260 |
| Postdose Day 449 | 864 ± 1290 |
| Postdose Day 456 | 0.0 ± 0.0 |
Testicular Echogenicity was determined by evaluating the sonographic patterns obtained on testicular ultrasound of right and left testes at baseline, Week 12, Week 36 and 64. The sonographic patterns were assessed by central imaging unit by an independent radiologist and categorized as Hypoechoic (decreased echogenicity as compared to echogenicity at baseline), Isoechoic (same echogenicity as compared to echogenicity at baseline) and Hyperechoic (increased echogenicity as compared to echogenicity at baseline). The number of participants with a sonographic pattern at Weeks 12, 36 and 64 were reported.
| Participants | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Left Testes: Baseline (BL) to Week 12: Hypoechoic | 2 |
| Left Testes: BL to Week 12: Isoechoic | 10 |
| Left Testes: BL to Week 12: Hyperechoic | 1 |
| Right Testes: BL to Week 12: Hypoechoic | 1 |
| Right Testes: BL to Week 12: Isoechoic | 12 |
| Left Testes: BL to Week 36: Hypoechoic | 2 |
| Left Testes: BL to Week 36: Isoechoic | 10 |
| Left Testes: BL to Week 36: Hyperechoic | 1 |
| Right Testes: BL to Week 36: Hypoechoic | 1 |
| Right Testes: BL to Week 36: Isoechoic | 9 |
| Right Testes: BL to Week 36: Hyperechoic | 3 |
| Left Testes: BL to Week 64: Hypoechoic | 2 |
| Left Testes: BL to Week 64: Isoechoic | 8 |
| Left Testes: BL to Week 64: Hyperechoic | 3 |
| Right Testes: BL to Week 64: Isoechoic | 10 |
| Right Testes: BL to Week 64: Hyperechoic | 3 |
LH is a gonadotropin secreted from the anterior pituitary and is a marker for spontaneous puberty. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in LH level to Weeks 12, 36 and 64.
| IU/L | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline | 0.25 ± 0.24 |
| Baseline to Week 12 | -0.08 ± 0.15 |
| Baseline to Week 36 | -0.13 ± 0.25 |
| Baseline to Week 64 | -0.14 ± 0.25 |
Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in T level to Weeks 12, 36 and 64. The change from baseline in T level to Week 12, 36, and 64 could not be calculated as planned because only 2 participants had baseline T level values which were insufficient to provide the trend change from baseline in T level to Week 12, 36, and 64.
No measurements were reported for this outcome.
Total T is a marker for progress of puberty in males. Total T levels increase during puberty as the testes respond to the gonadotropins. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 post dose to report the mean change from baseline in Total T level to Weeks 12, 36 and 64. A negative value indicated a lower Total T level.
| ug/L | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline | 0.11 ± 0.12 |
| Baseline to Week 12 | -0.01 ± 0.07 |
| Baseline to Week 36 | 4.87 ± 3.97 |
| Baseline to Week 64 | 5.31 ± 3.31 |
E2 levels rise during puberty in males when some of the T secreted is aromatized. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in E2 level to Weeks 12, 36 and 64. A positive value indicated a higher E2 level.
| ng/L | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline | 9.51 ± 0.00 |
| Baseline to Week 12 | 0.81 ± 2.90 |
| Baseline to Week 36 | 37.57 ± 28.73 |
| Baseline to Week 64 | 45.58 ± 41.09 |
SHBG is a blood protein that controls the amount of T body tissues in males. SHBG is regulated by the ratio of T and E2 levels in addition to other factors (thyroid hormone status, dietary factors, certain diseases and medications). Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in SHBG level to Weeks 12, 36 and 64. A negative value indicated a lower SHBG level.
| ug/dL | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline | 1.53 ± 0.91 |
| Baseline to Week 12 | 0.04 ± 0.45 |
| Baseline to Week 36 | -0.53 ± 0.73 |
| Baseline to Week 64 | -0.68 ± 0.76 |
AMH is a marker for progress of puberty in males. Blood samples were collected at baseline, Week 12, Week 36 and Week 64 to report the mean change from baseline in AMH level to Weeks 12, 36 and 64. A negative value indicated a lower AMH level.
| ug/L | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Baseline | 23.62 ± 11.07 |
| Baseline to Week 12 | 17.98 ± 8.39 |
| Baseline to Week 36 | -10.23 ± 15.69 |
| Baseline to Week 64 | -15.83 ± 11.58 |
Collected over All-cause mortality, serious and non-serious AEs were collected for up to approximately 71 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) | 0/17 (0%) | 1/17 (5.9%) | 16/17 (94.1%) |
| Event | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| CraniopharyngiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/17 |
| Event | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Oestradiol increasedInvestigations | 5/17 |
| SpermatoceleReproductive system and breast disorders | 5/17 |
| Blood testosterone increasedInvestigations | 4/17 |
| HeadacheNervous system disorders | 4/17 |
| DiarrhoeaGastrointestinal disorders | 2/17 |
| VomitingGastrointestinal disorders | 2/17 |
| NasopharyngitisInfections and infestations | 2/17 |
| Upper respiratory tract infectionInfections and infestations | 2/17 |
| Blood testosterone decreasedInvestigations | 2/17 |
| Blood testosterone free increasedInvestigations | 2/17 |
Male participants with Hypogonadotropic Hypogonadism (HH) aged 14 to \<18 years were enrolled in the study.
| Age, Continuous(years) | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Mean | 15.5 ± 0.9 |
| Sex: Female, Male(Participants) | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Female | 0 |
| Male | 17 |
| Ethnicity (NIH/OMB)(Participants) | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 13 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 16 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Testicular Volume (TV)(mL) | Corifollitropin Alfa (CFA)+Human Chorionic Gonadotropin (hCG) |
|---|---|
| Mean | 2.2 ± 1.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in May 2020, 39 months.
Results were first posted in Apr 2021, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Corifollitropin alfa · Chorionic Gonadotropin